Literature DB >> 2372992

Modulation of leucocyte locomotion by interleukin-1.

C C Zielinski1, B Pesau, W Kalinowski, C Müller.   

Abstract

The influence of interleukin-1 (IL-1) upon leucocyte locomotion in vitro was studied, using either casein or zymosan-activated serum (ZAS) as chemotaxigens. A pre-incubation of polymorphonuclear cells (PMNC) with ultrapure (purity 99%) human IL-1 (1 U/ml) for 2 and 5 h followed by a washing step resulted in a significant decrease in leucocyte locomotion against casein (P less than 0.0005 and P less than 0.01, respectively), but not against ZAS (P greater than 0.1). Moreover, the direct addition of this IL-1 preparation to leucocyte locomotion assays without pre-incubation produced a similar and significant inhibition of leucocyte locomotion directed against casein (P less than 0.05). This inhibitory effect could not be augmented further by higher concentrations of ultrapure IL-1. In order to exclude the effect of possibly contaminating cytokines in the ultrapure IL-1 preparation used, additional assays with recombinant human IL-1 (rIL-1) alpha and rIL-1 beta (1 U/ml) were performed to investigate their influence upon leucocyte locomotion. It was found that both rIL-1 alpha and rIL-1 beta inhibited leucocyte locomotion directed against casein significantly (P less than 0.005). Similar to the previous experiments, leucocyte locomotion could not be further inhibited by higher concentrations (10 U/ml) or rIL-1. Thus, both ultrapure and rIL-1 were found to have the ability to inhibit leucocyte locomotion in vitro.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2372992      PMCID: PMC1535183          DOI: 10.1111/j.1365-2249.1990.tb03307.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  12 in total

1.  Serum associated leucocyte locomotion inhibition and leucocyte motility in malignant melanoma: effect of BCG treatment.

Authors:  C Zielinski; H Pehamberger; A T Endler; W Knapp
Journal:  Clin Exp Immunol       Date:  1979-10       Impact factor: 4.330

Review 2.  Acute inflammation and microthrombosis induced by endotoxin, interleukin-1, and tumor necrosis factor and their implication in gram-negative infection.

Authors:  M I Cybulsky; M K Chan; H Z Movat
Journal:  Lab Invest       Date:  1988-04       Impact factor: 5.662

Review 3.  Interleukin-1 and the pathogenesis of the acute-phase response.

Authors:  C A Dinarello
Journal:  N Engl J Med       Date:  1984-11-29       Impact factor: 91.245

Review 4.  Interleukin 1 and T cell activation.

Authors:  S B Mizel
Journal:  Immunol Rev       Date:  1982       Impact factor: 12.988

5.  Role of the classical and alternative complement pathways in chemotaxis and opsonization: studies of human serum deficient in C4.

Authors:  R A Clark; S J Klebanoff
Journal:  J Immunol       Date:  1978-04       Impact factor: 5.422

6.  Human recombinant interleukin 1 beta has no effect on intracellular calcium or on functional responses of human neutrophils.

Authors:  K Georgilis; C Schaefer; C A Dinarello; M S Klempner
Journal:  J Immunol       Date:  1987-05-15       Impact factor: 5.422

7.  Cultured human vascular endothelial cells acquire adhesiveness for neutrophils after stimulation with interleukin 1, endotoxin, and tumor-promoting phorbol diesters.

Authors:  R P Schleimer; B K Rutledge
Journal:  J Immunol       Date:  1986-01       Impact factor: 5.422

8.  Chemotactic properties of partially purified human epidermal cell-derived thymocyte-activating factor (ETAF) for polymorphonuclear and mononuclear cells.

Authors:  T A Luger; J A Charon; M Colot; M Micksche; J J Oppenheim
Journal:  J Immunol       Date:  1983-08       Impact factor: 5.422

9.  Neutrophil leukocyte emigration induced by endotoxin. Mediator roles of interleukin 1 and tumor necrosis factor alpha 1.

Authors:  M I Cybulsky; D J McComb; H Z Movat
Journal:  J Immunol       Date:  1988-05-01       Impact factor: 5.422

10.  The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leucocytes.

Authors:  S BOYDEN
Journal:  J Exp Med       Date:  1962-03-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.